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After recent randomized control trials (RCTs), non-vitamin K oral anticoagulants (NAOAs) are now 
widely being used in patients with atrial fibrillation (AF) worldwide. However, current guidelines for 
the use of NOACs in patients with AF are derived mostly using a Caucasian population and non-
stroke patients. Relatively few Asian patients with AF and stroke are included in the recent RCTs. As 
a result, the optimal use of NOACs in this particular group of patients is remains to be settled. The 
optimal dose of NOACs and response to current dose of NOACs of Asian patients with AF and stroke 
may differ from those of westerners and patients without stroke. We reviewed available research on 
NOACs by searching PubMed and ClinicalTrials.gov published in English up to December 2015. In 
this review, the characteristics of Asian AF patients with prior stroke/transient ischemic attack, 
which might influence the efficacy and safety profiles of NOACs, are discussed. In addition, we sum-
marize the risk factors for bleeding complications on NOACs, which are related or unrelated with the 
blood level of NOACs. Lastly, we provide recent data of reduced dose of NOACs from RCTs or large 
cohorts. The results reviewed herein call for clinical trials to test whether a reduced dose of NOACs 
is beneficial in Asian patients with AF and stroke. In the meantime, further researches are needed to 
establish the safety and efficacy of dose-adjusted NOACs considering both blood levels of NOACs 
and fragility of patients in Asian patients with AF and stroke.
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Review
Introduction
Large randomized controlled trials (RCTs) consistently showed 
that non-vitamin K antagonist oral anticoagulants (NOACs) were 
at least as effective and safe as (regarding intracranial bleeding, 
much safer than) warfarin for stroke prevention in atrial fibrilla-
tion (AF),1-4 and regulatory authorities in many countries have 
approved NOACs. As a result, NOACs are now increasingly and 
widely being used worldwide. However, even with NOACs, the 
risk of major bleeding complication is not negligible; the annual 
major bleeding rates in the landmark RCTs were 2.71% and 
3.11% with low and high dose dabigatran, 3.13% with rivaroxa-
ban, 2.8% with apixaban, and 1.61% and 2.75% with low and 
high dose edoxaban.1-4
Patients enrolled in RCTs are only partly representative of pa-
tients with AF in clinical practice.5 Furthermore, Asian AF patients 
with prior stroke or transient ischemic attack (TIA) constituted 
the minority of patients enrolled in the RCTs; 10.7% were Asians 
(from 6.5% of the ROCKET-AF trial to 15.4% of the RE-LY trial),6-9 
20.3% were patients with prior stroke or TIA (from 18.9% in the 
ARISTOTLE trial to 52.4% of the ROCKET-AF trial),10-12 and there-
by only 3.7% were Asian patients with prior stroke or TIA.13 
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The relative efficacy and safety of NOACs over warfarin appear 
to be greater in Asians than in non-Asians,13-15 but the bleeding 
rates with NOACs were higher in Asians than in non-Asians. 
Therefore, the optimal dose and response to the currently recom-
mended dose of NOACs in Asian AF patients with prior stroke/TIA 
may differ from those in non-Asians and those without prior 
stroke/TIA. 
In this review, we will discuss the characteristics of Asian AF 
patients with prior stroke/TIA, which might influence the efficacy 
and safety profiles of NOACs. In addition, we will summarize the 
risk factors for bleeding complications on NOACs, which are re-
lated or unrelated with the blood level of NOACs. Lastly, we will 
provide recent data of reduced dose of NOACs from RCTs or 
large cohorts. 
Search strategy and selection criteria
We identified references for this review by searching PubMed 
and ClinicalTrials.gov published in English up to December 2015, 
with the search terms of AF, anticoagulation, Asians, stroke, ce-
rebral infarction, bleeding, and hemorrhage. Additional relevant 
articles were identified from manual searches of relevant articles 
and reviews and were solicited from the authors. The final refer-
ence list was generated on the basis of originality and relevance 
to this topic. Because of space limitation, we were not able to 
include the results of small cohort studies and we described the 
results of RCTs only briefly. 
Summary of efficacy and safety 
findings from representative studies
Table 1 summarizes the findings of efficacy and safety end-
points from representative RCTs, cohort studies, and meta-anal-
yses.
In a meta-analysis of overall populations including Asians and 
non-Asians enrolled in 4 major RCTs,16 high-dose NOACs com-
pared to warfarin significantly reduced stroke or systemic embo-
lism by 19% (risk reduction 0.81, 95% CI 0.73-0.91; P<0.001) 
Table 1. Summary of risk of stroke/thromboembolism and major bleeding with and without dose reduction of non-vitamin K oral anticoagulants and 
warfarin
NOAC vs. warfarin No. of patients
Primary end point Bleeding complications
HR (95% CI) HR (95% CI)
Stroke or SE Major bleeding ICH G-I bleeding
RE-LY trial
   Dabigatran 150 mg 6,076 0.66 (0.53-0.82) 0.93 (0.81-1.07) 0.40 (0.27-0.60) 1.50 (1.19-1.89)
   Dabigatran 110 mg   6,015 0.91 (0.74-1.11)* 0.80 (0.55-0.83)* 0.31 (0.20-0.47) 1.10 (0.86-1.41)*
U.S. Medicare data (propensity-matched)
   Dabigatran 150 mg 56,576 0.70 (0.57-0.85) N/A 0.30 (0.21-0.42) 1.51 (1.32-1.73)
   Dabigatran 75 mg 10,522 0.88 (0.60-1.27) N/A 0.46 (0.26-0.81) 1.01 (0.78-1.31)
Taiwan national health insurance data (propensity-matched)
   Dabigatran 150 mg 1,168 0.61 (0.37-1.00) N/A 0.22 (0.06-0.76) 1.05 (0.29-3.76)
   Dabigatran 110 mg   8,772 0,62 (0.52-0.75)* N/A 0.47 (0.34-0.65) 0.99 (0.64-1.52)
ROCKET-AF trial
   Rivaroxaban (20 mg in 79.4%) 7,081 0.79 (0.66-0.96) 1.04 (0.90-1.20) 0.67 (0.47-0.93) N/A
   Rivaroxaban (15 mg J-ROCKET) 1,280 0.49 (0.24-1.00) 0.85 (0.50-1.43) 0.73 (0.16-3.25) N/A
ARISTOTLE trial (Apixaban) 9,120 0.79 (0.66-0.95) 0.68 (0.61-0.75) 0.42 (0.30-0.58) 0.89 (0.70-1.15)
ENGAGE AF-TIMI 48 trial
   Edoxaban 60 mg 5,251 0.87 (0.73-1.04) 0.80 (0.71-0.91) 0.47 (0.34-0.63) 1.23 (1.02-1.50)
   Edoxaban 30 mg 1,784 1.13 (0.96-1.34)* 0.47 (0.41-0.55)* 0.30 (0.21-0.43)* 0.67 (0.53-0.83)*
Meta-analysis (Ruff et al. 2014)
   High-dose NOACs 29,287 0.81 (0.73-0.91) 0.86 (0.73-1.00) 0.48 (0.39-0.59) 1.25 (1.01-1.25)
   Low-dose NOACs 13,049 1.03 (0.84-1.27) 0.65 (0.43-1.00) 0.31 (0.24-0.41) 0.89 (0.57-1.37)
Meta-analysis (Wang et al. 2015)
   Standard dose of NOACs in Asians 3,035 0.65 (0.52-0.83) 0.57 (0.44-0.74) 0.33 (0.22-0.50) 0.79 (0.48-1.32)
   Low dose of NOACs in Asians 2,216 0.93 (0.71-1.21) 0.52 (0.32-0.86) 0.28 (0.16-0.49) 0.67 (0.39-1.15)
   Standard dose of NOACs in non-Asians 26,277 0.85 (0.77-0.93) 0.89 (0.76-1.04) 0.52 (0.42-0.64) 1.44 (1.12-1.85)
   Low dose of NOACs in non-Asians 11,473 1.07 (0.93-1.24) 0.64 (0.38-1.09) 0.32 (0.24-0.44) 0.87 (0.56-1.35)
The meta-analysis for standard vs. low dose NOACs included data of dabigatran 150 vs. 110 mg, edoxaban 60 vs. 30 mg, and rivaroxaban 20 vs. 15 mg.
NOAC, non-vitamin K oral anticoagulant; HR, hazard ratio; CI, confidence interval; SE, systemic embolism; ICH, Intracranial bleeding; G-I, Gastrointestinal; N/A, 
 not assessed.
*Significant difference between two dose groups.
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and intracranial hemorrhage by 52% (0.48, 0.39-0.59; P <  
0.001), and there were no heterogeneity across the trials. How-
ever, the reduction of major bleeding with high-dose NOACs was 
non-significant (0.86, 0.73-1.00; P=0.06), and there was signifi-
cant heterogeneity across the trials. Gastrointestinal bleeding 
was significantly increased with high-dose NOACs (1.25, 1.01-
1.55; P=0.043), but significant heterogeneity was noted. In con-
trast, low-dose NOACs (110 mg dabigatran and 30/15 mg edoxa-
ban) compared to warfarin had similar risk of stroke or systemic 
embolism (1.03, 0.84-1.27; P=0.74) and higher risk of ischemic 
stroke (1.28, 1.02-1.0; P=0.045), but had comparable risk of 
gastrointestinal bleeding (0.89, 0.57-1.37; P=0.58), non-signifi-
cant reduction in major bleeding (0.65, 0.43-1.00; P=0.05), and 
substantial reduction in intracranial hemorrhage (0.31, 0.24-
0.41; P<0.001).
The relative safety and efficacy of NOACs compared to warfa-
rin may be greater in Asians than in non-Asians, especially in 
stroke patients.14,15 In a recent meta-analysis,17 Asians had great-
er benefits of high-dose NOACs over warfarin than non-Asians 
for the endpoints of stroke or systemic embolism (odds ratio 
[95% CI], 0.65 [0.52-0.83] vs. 0.85 [0.77-0.93]; P interac-
tion=0.045), major bleeding (0.57 [0.44-0.74] vs. 0.89 [0.76-
1.04], P interaction=0.004), and hemorrhagic stroke (0.32 [0.19-
0.52] vs. 0.56 [0.44-0.70], P interaction=0.046). While the risk 
of gastrointestinal bleeding was higher with high-dose NOACs 
than with warfarin in non-Asians (1.44 [1.12-1.85]), but not in 
Asians (0.79 [0.48-1.32]) (P interaction=0.041). In contrast, 
when comparing low-dose NOACs compared to warfarin, Asians 
and non-Asians did not differ in the results of efficacy and safety 
endpoints (Table 1). 
In patients randomized to NOACs, Asians versus non-Asians 
had numerically lower rates of major bleeding except for those 
on edoxaban 60 mg (Figure 1). However, the risks of intracranial 
hemorrhage, the most devastating complication, were higher in 
Asians than in non-Asians (the annual risk difference from 0%/
year to 0.37%/year) and greater in patients with prior stroke/TIA 
than in those without (the annual risk difference from 0.2%/year 
to 0.26%/year) (Figure 2).6-9 Therefore, these results suggest that 
intracranial hemorrhage rather than major bleeding (including 
gastrointestinal bleeding) is a major concern in selection and 
dosing of NOACs in Asians. Asian AF patients with prior stroke/
TIA who are likely to have fragile cerebrovascular bed might have 
greater risk of intracranial hemorrhage, but until now no analysis 
has been specifically conducted for these patients.
A
Major bleeding rate (%/year)
Ra
te
 (%
/y
ea
r)
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2.84 2.61
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Figure 1. Annual rates of major bleeding with NOACs in (A) Asians vs. non-Asians and (B) patients with prior stroke/TIA vs. patients without from AF 
RCTs.
Figure 2. Annual rates of intracranial hemorrhage with NOACs in (A) Asians vs. non-Asians and (B) patients with prior stroke/TIA vs. patients without 
from AF RCTs.
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Characteristics of Asians patients with 
stroke and atrial fibrillation 
In multinational survey or cohort studies, Asian AF patients 
were more likely to have a history of prior stroke/TIA and lower 
body weights (or less obesity) than non-Asian AF patients.18-21 In 
a Japanese community-based registry of AF patients, the mean 
age was 74.2 years, the mean body weight was 58.5 kg, 21.8% 
had a history of stroke/TIA, and the mean creatinine clearance 
(CrCl) was 63.4 mL/min and 35.6% had moderate to severe renal 
impairment ( <30 mL/min in 11.4% and 30-50 mL/min in 
24.2%).22 Similarly, among patients enrolled in 4 RCTs of NOACs, 
Asians had more history of stroke/TIA (despite the comparable 
CHADS2 score) and substantially lower body weights than non-
Asians (Figures 3 and 4).6-9 The difference in body weight be-
tween Asians and non-Asians was 20 kg in RE-LY, 16 kg in 
ROCKET-AF, 17 kg in ARISTOTLE, and 20 kg in ENGAGE-AF TIMI 
48. Body weight, along with serum creatinine level, age and sex 
determines CrCl, which significantly influence NOACs metabo-
lism. Of note, the proportions of patients with mild (CrCl 50-80 
mL/min) or moderate (CrCl 30-50 mL/min) renal impairment 
were higher in Asians than in non-Asians.6-9,23
Among Asian patients with AF, characteristics are likely to dif-
fer between patients with a history of stroke/TIA and those with-
out, but no study has conducted formal comparison. In a Japa-
nese multicenter registry of acute ischemic stroke patients with 
AF, the mean age was 77.7 years, the mean body weight was 
56.3 kg, and the mean CrCl was 56.6 mL/min.24 Despite the limi-
tation of indirect comparison, Japanese AF patients with stroke/
TIA compared to Japanese overall AF patients appear to have 
higher age, lower body weight, and lower renal function.22,24 In a 
single center study of Korea, AF patients with stroke/TIA had a 
mean age of 73.9 years and CrCl of 56.8 mL/min,5 which were 
similar to those of Japanese AF patients with stroke/TIA. In this 
study, when the enrollment criteria of four RCTs were applied to 
Korean patients with AF, the proportion of patients excluded 
from trials were expected to be higher in patients with stroke/
TIA (27.2%-42.6%, depending on individual trial’s criteria) vs. 
those without stroke/TIA (18.5%-27.2%). The main reasons for 
ineligibility for RCTs in patients with stroke/TIA were high of 
bleeding risk (15.2%-20.8%) and low CrCl (5.6%-9.2%).5 
Compared to non-Asians, Asians are at higher risk of warfarin-
related intracranial bleeding,25 and the prevalence of intracranial 
macro- and microangiopathy also appears to be high.26-28 For ex-
ample, cerebral microbleeds, which are high prevalent in Asians 
and stroke patients, increase the risk of intracranial bleeding with 
warfarin use.29-31 Individualized antithrombotic therapy, e.g., use 
of NOACs, was proposed depending on the presence of and in-
crease in the number of cerebral microbleeds on brain MRI.32,33 
Previous ischemic stroke or TIA is the most powerful indepen-
dent risk factor for stroke in patients with AF.34 The early period 
after acute ischemic stroke or TIA is particularly at high risk of 
recurrent stroke, but also at high risk of intracranial bleeding. 
Furthermore, a large population-based study showed an in-
creased risk of stroke during the early period of warfarin initia-
tion,35 possibly due to prothrombotic activity of warfarin at 
treatment initiation.36 For anticoagulation in acute cerebral isch-
emia, NOACs might be better than warfarin. However, patients 
with recent stroke/TIA were largely excluded in the landmark 
NOAC AF trials: the cut-off time point for eligibility from stroke 
onset to randomization was 30 days in ENGAGE-AF, 14 days in 
RE-LY and ROCKET-AF, and 7 days in ARISTOTLE. As a result, data 
about the use of NOACs in patients with recent stroke are lack-
ing. Currently, a randomized trial is ongoing to examine the 
safety and efficacy of early initiation (within 5 days from stroke 
onset) of rivaroxaban in patients with AF and acute ischemic 
stroke (TripleAXEL, NCT02042534).37 
In patients with AF, stroke is not always caused by cardiogenic 
embolism (AF-unrelated mechanism). Since macro- and micro-
angiopathies are more prevalent in Asians than in non-Asians, 
Non-Asians         Asians Non-Asians         Asians
Figure 3. Patients with a prior stroke/TIA enrolled in NOACs RCTs.
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Figure 4. Body weight of patients enrolled in NOACs RCTs.
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AF-unrelated stroke/TIA is more likely to occur in Asian AF pa-
tients than in non-Asian AF patients. In a Korean study, among 
AF patients with recent ischemic stroke, 17.2% of ischemic 
strokes were classified as AF-unrelated strokes.38 Moreover, com-
pared to patients with AF-related stroke, patients with AF-unre-
lated stroke experienced more recurrent strokes even with ade-
quate anticoagulation, and 87.5% of their recurrent strokes were 
AF-unrelated strokes.38 Therefore, it would be of clinical rele-
vance to differentiate stroke mechanism in AF patients. A recent 
multidetector cardiac computed tomography study showed that 
morphometric and volumetric changes of left atrial appendage 
was not prominent in AF-unrelated stroke.39 For patients with 
AF-related stroke, antiplatelet drugs should be discontinued at 
the time of NOACs initiation unless there is a strong indication 
other than secondary stroke prevention for their continuous use. 
However, antiplatelet therapy might be often needed in patients 
with AF-unrelated stroke, particularly during the early period af-
ter acute cerebral ischemia.
Annual risk of stroke in individuals with AF is a continuum and 
increases with risk factors. The CHADS2 and CHA2DS2-VASc 
schemes are most widely used model for stratification of AF-re-
lated stroke risks, but a high score would also indicate a higher 
atherosclerotic burden. Previous studies showed that high 
CHADS2 and CHA2DS2-VASc scores were associated with subse-
quent stroke, cardiovascular events, and death in stroke patients 
without AF40 and in acute coronary syndrome patients.41 Thereby, 
AF patients with high CHADS2 or CHA2DS2-VASc scores might 
have a higher risk of AF-unrelated stroke (macro- or microangi-
opathy).42,43 A large Chinese cohort of AF patients showed that 
although net benefit favor warfarin over antiplatelet for patients 
at high risk of stroke, the benefit of warfarin decreased with the 
increase in the CHA2DS2-VASc scores.44 
Therefore, concomitant use of antiplatelet agents are often 
needed in Asian stroke patients with AF. In the RE-LY trial, Asians 
had a higher rate of previous stroke (24.2% vs. 10.4%) and use 
of antiplatelet agents (47.1% vs. 38.1%) than non-Asians.6 Con-
comitant use of antiplatelet agents and anticoagulants increase 
the bleeding risks. A meta-analysis of patients receiving anti-
platelet therapy after an acute coronary syndrome showed that 
the use of NOACs is associated with a dramatic increase (~3 
times) in major bleeding events.45
Dose of NOACs: serum level vs. fragility 
of patients 
Renal function, a major determinant of serum NOAC 
levels
Based on the study design and results of subgroup analysis of 
RCTs of NOACs, current guidelines of AF management recom-
mended dose reduction according to the serum level of NOACs.46 
Because NOACs are predominantly or partially excreted by the 
kidneys, only patients with CrCl ≥30 mL/min (dabigatran and ri-
varoxaban) or ≥25 mL/min (apixaban) were included in the tri-
als. The studies with apixaban and rivaroxaban used reduced 
doses for patients with CrCl <50 mL/min. Age (>80 years) for 
dabigatran and apixaban, body weight (≤60 kg) for apixaban 
and edoxaban, and the use of P-glycoprotein antagonist (e.g., 
dronedarone) were also considered in selection of NOAC dose. 
Both age and body weight are parameters used to estimate CrCl 
by Cockcroft-Gault equation, and absorption of NOACs is depen-
dent on the intestinal P-glycoprotein system.
However, the benefits of the NOACs seem to be larger in 
chronic kidney disease stages.47 In the ARISTOTLE trial, relative 
reduction in major bleeding was greater in patients with renal 
dysfunction.48 For Asian patients with stroke, data about bleed-
ing risk depending on the renal function is limited. In Asian pa-
tients in the RE-LY trial, bleeding rate was increased with renal 
impairment, but relative benefits of dabigatran over warfarin 
were preserved regardless of renal function.49
Comorbid conditions of patients, major determinants 
of bleeding complications
Safe use of NOACs needs understanding of when to reduce 
the dose of NOACs. In this context, it is possible that fragility of 
patients (clinical and radiological features) may be as important 
as serum NOAC levels (related to renal function) in the develop-
ment of major bleeding during the use of NOACs. 
Post-hoc analysis of RCTs showed determinants of major 
bleeding in NOAC users. Elderly, prior stroke, prior gastrointesti-
nal bleeding/anemia, aspirin use, renal dysfunction, and multiple 
cerebral microbleeds were commonly associated with major 
bleeding.50-52 Patients with AF and stroke often have comorbid 
conditions and take multiple medications. In ROCKET AF, two-
thirds of enrolled patients were on ≥5 medications, and the 
bleeding risk increased as the medication numbers increased.53 In 
RE-LY, concomitant antiplatelet drugs increased the risk of major 
bleeding, and the major bleeding risk was higher with dual anti-
platelet therapy than with single antiplatelet therapy. Of patients 
who had concomitant antiplatelet use, the major bleeding risk 
was lowest in low dabigatran user (dabigatran 110 mg, BID).54
It is interesting that many of the factors are relatively unrelat-
ed to the degree of renal impairment, suggesting the importance 
of consideration of ‘non-renal’ factors as well as renal factor 
when considering the dose of NOACs (Figure 5).
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Results of low doses of warfarin and 
non-vitamin K oral anticoagulants  
Need for a low level of anticoagulation in frail 
patients
Anticoagulation therapy is needed even in frail patients with 
AF who have an increased risk of bleeding. A Japanese commu-
nity-based survey (Fushimi AF registry) showed that features 
suggesting fragility of patients (i.e., advanced age, underweight, 
previous stroke, heart failure, chronic kidney disease, and ane-
mia) were independently associated with risk of stroke and death 
in non-anticoagulated patients.55 In post-hoc analysis of ROCK-
ET-AF, renal dysfunction was a strong, independent predictor of 
stroke and systemic embolism and a risk estimation scheme in-
corporating renal dysfunction (R2CHADS2 score) better predicted 
the risk of stroke or systemic embolism in ROCKET-AF and ATRIA 
(AnTicoagulation and Risk factors In Atrial fibrillation) popula-
tions.56
A Japanese study (J-RHYTHM registry) showed that warfarin 
could have beneficial effects even in very old patients with AF if 
INR is kept between 1.6 and 2.59, suggesting importance of a 
lower level of anticoagulation in frail patients.57
The benefits of NOACs compared with warfarin in the elderly 
individuals with multiple comorbid conditions were consistently 
observed among the trials.58 NOACs appear promising and help 
overcome some if not all of the limitations of warfarin in early 
frail patients.58 In fact, the clinical benefits of NOACs may be 
greater in patients with high bleeding risk.59 Proposals for deci-
sion-making in NOACs use for these frail/high bleeding risk pa-
tients were recently suggested.58-60 However, in the real world, 
NOACs were underutilized in these patients (e.g., elderly).61,62 Our 
results of Korean patients with AF and stroke showed that there 
was a negative correlation between CrCl and ATRIA score (a 
scheme for bleeding-risks), and patients who had features favor-
ing NOAC use (i.e., a high ATRIA score) were more likely to have 
contraindications for NOACs use (i.e., a low CrCl).5 
Evidences from randomized controlled trial 
RCTs and large cohort studies have evaluated the safety and 
efficacy of different doses of NOACs in patients with AF. In par-
ticular, the RE-LY and ENGAGE AF-TIMI 48 trials formally tested 
two different doses of NOACs (Table 1).
In the J-ROCKET-AF study, 15 mg rivaroxaban instead of 20 
mg was used,63 because 15 mg rivaroxaban dose in Japanese pa-
tients yield exposures comparable to 20 mg dose in white pa-
tients.64 The trial results demonstrated noninferiority of 15 mg 
rivaroxaban and less intracranial bleeding over warfarin, which 
supports the use of a reduced dose of rivaroxaban (15 mg) for 
evaluation in Japanese patients with AF.63
The ENGAGE AF-TIMI 48 trial evaluating the efficacy of edoxa-
Figure 5. Factors associated with major or intracranial bleeding in RCTs of NOAC trials and their relationships. Black outlines represent fragility in 
Asian patients with stroke, whereas red outlines represent factors that determined serum levels of NOACs. CMBs, cerebral microbleeds.
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ban vs. warfarin in patients with AF provided the evidence of 
supporting the use of a lower dose of NOAC in fragile patient 
population.4,65 In this study, low-dose (30 mg vs. 60 mg) edoxa-
ban was associated with a 41% increase in ischemic stroke, 
which is counterbalanced by a 53% reduction in hemorrhagic 
stroke, suggesting an Importance of the low dose of NOACs in 
fragile patient populations that present with greater risk of hem-
orrhagic stroke. Despite the lower anti-factor Xa activity, dose re-
duction preserved the efficacy of edoxaban compared with war-
farin, suggesting that the therapeutic window for edoxaban is 
narrower for major bleeding than thromboembolism.65 One re-
cent Japanese study showed that bleeding rate, plasma edoxaban 
concentration and biomarkers of blood coagulation and fibrino-
lysis were similar between patients with severe renal impairment 
receiving low dose edoxaban (15 mg) and those with normal re-
nal function receiving a higher dose edoxaban (30 or 60 mg).66 
Similar results were also observed in the RE-LY trial that 
showed dose reduction of dabigatran significantly increased in 
stroke or systemic embolism but a significant reduction in major 
bleeding.1 However, further studies are needed because, in the 
recent study of propensity score matched elderly patients en-
rolled in Medicare, neither stroke/systemic embolism nor intra-
cranial/major gastrointestinal bleeding were significantly differ-
ent between patients received dabigatran 150 mg vs. 75 mg 
twice daily.67 Very recently, the Taiwan national health insurance 
research database showed that 88% patients took 110 mg dabi-
gatran and the magnitude of effect for outcomes of 110 mg was 
comparable with those of 150 mg dose in real-world practice.68
A recent meta-analysis of RCTs of NOACs comparing efficacy 
and safety of NOACs between patients enrolled in Asian and 
non-Asian countries showed that standard-dose NOACs are pre-
ferred over warfarin in Asians patients, whereas low-dose NOACs 
are effective and safe alternative to warfarin.17
Perspectives and conclusions
Current guidelines for the use of NOACs in patients with AF 
are largely derived from Caucasian and non-stroke patients. 
Asian patients with AF and stroke might be ‘specific’ AF popula-
tion due to ‘specific’ profiles of higher risks of both thromboem-
bolic and bleeding events, and both patients and physicians are 
often reluctant to use NOACs as well as warfarin due to fear of 
bleeding complications. However, no specific guidelines exist re-
garding the dose of NOACs in these patients.69,70 Measurement 
of serum levels of NOACs and anti-IIa or anti-Xa activity may 
improve safety during NOAC therapy, but not available in clinical 
practice yet. Several clinical and radiological features related 
bleeding complications may provide additional information to 
current guideline (dose reduction according to renal function to 
achieve optimal serum NOAC levels) in the selection of dose of 
NOACs.
Available data reviewed herein suggest that anticoagulation 
with NOACs could be promising and help overcome limitations 
of warfarin, especially in elderly frail patients, such as Asian pa-
tients with AF and stroke. Although the dose of NOACs should 
be used under the current guidelines for NOAC use in patients 
with AF, emerging evidences suggested that a reduced dose of 
NOACs could be helpful in these patients. To date, no studies 
have been conducted to test whether a reduced dose of NOACs 
is beneficial in Asian patients with AF and stroke. Because head-
to-head comparisons of NOACs regarding their efficacy in pre-
venting stroke in these particular patients are lacking, a recom-
mendation for a preferred use of any of the NOACs can not be 
made. In the meantime, further researches are needed to estab-
lish the safety and efficacy of dose-adjusted NOACs considering 
both blood level of NOACs and fragility of patients in Asian pa-
tients with AF and stroke.
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